Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Can't Decide Whether Agency Should Issue Nanotechnology Guidance

This article was originally published in The Gold Sheet

Executive Summary

Do nanotechnology-derived drugs merit their own GMPs? That remains an open question, say FDA advisors, unsure whether nanoguidance is warranted.

You may also be interested in...

Efforts Mount to Assure Quality of Emerging Pharma Technologies

The regulatory challenges of emerging technologies are triggering an evolution in CMC review and GMP compliance approaches as regulatory agencies, drug manufacturers and standard-setting organizations strive to adapt 20th century concepts to 21st century science. FDA unveils an initiative to close ‘regulatory science’ gaps, while EMA drafts a road map for adapting its regulatory framework to novel scientific approaches. PQRI considers opportunities to contribute its scientific expertise at the government/industry nexus. The CMC Strategy Forum explores new approaches for antibody-drug conjugates. FDA launches nanotechnology initiative; CDER’s concerns about nanoparticles shared. FDA approves first ‘biopharm’ product, prepares for wave of applications. Manufacturing quality issues with transgenic bioreactors explored in context of GTC’s goat farm. How milking animals compares to milking CHO cells. On biosimilars, U.S. legislation stalls while the EU forges ahead with reviewing applications – and Japan declares a preference for ‘bio-betters.’ Meanwhile, the science for supporting bio-comparison remains lost in the folds of higher order structure. All could be clarified by NIST’s ambitious reference standard proposal.

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts